At Mayo Clinic Laboratories, we believe all patients deserve access to world-class diagnostic care. We work with hospitals and healthcare providers around the world to deliver unparalleled expertise and innovative diagnostic evaluations that solve the most complicated cases.
Fully integrated with Mayo Clinic and backed by more than 150 years of clinical experience, Mayo Clinic Laboratories was built upon a tradition of knowledge sharing to improve healthcare around the world. When you work with us, you gain access to the world’s most sophisticated test menu, world-renowned experts, and educational opportunities to strengthen your practice, advance knowledge, and improve patient outcomes.
Focused on quality
At Mayo Clinic Laboratories, test development is based on patient need and guided by quality management protocols modeled on standards and guidelines from the Clinical and Laboratory Standards Institute. Our extensive test validation includes a breadth of specimens with rare abnormalities. Our laboratories are CLIA-certified and CAP-accredited, and we participate in U.S. and international proficiency programs.
Commitment to education
The exchange of knowledge is a founding principle of Mayo Clinic. In this tradition, we provide a wide range of educational offerings to help our clients increase understanding.
Enhanced patient outcomes
Mayo Clinic Laboratories is dedicated to the health and well-being of our patients, which means helping providers deliver care in their local settings through the utilization of our comprehensive subspecialty test menu. Our mission is grounded in our belief that the patient’s needs are paramount, and our clients receive access to:
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S., a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy.
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
A major winter storm will move across the West Coast and Upper Midwest through Thursday, Feb. 23. We are monitoring and tracking the situation with our logistics partners to minimize challenges.
On this episode of Mayo Clinic Laboratories “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, sits down with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton to delve deeper into the world of outreach program management. As true pioneers of the department at Mayo Clinic, Ellen and Brianne share their robust knowledge and experience on the journey to becoming an outreach leader.
In this month's "Hot Topic," Eoin Flanagan, M.B., B. Ch., discusses the important issue of autoimmune encephalitis misdiagnosis and identifies red flags that be useful in clinical practice to suggest alternative diagnoses and highlight antibodies that sometimes cause confusion.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with Dr. Nour Al-Mozain, a hematopathologist and transfusion medicine consultant at King Faisal Specialist Hospital in Riyadh, Saudi Arabia, about the importance of reaching out to colleagues for advice.
Outreach management is not taught in a formal training program. The path can be diverse, with different means and methods for success. Whether you inherited an outreach program or have built one from the ground up, here are seven tips to improve your success.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.
Mayo Clinic Laboratories expanded movement disorders panel better identifies autoimmune conditions. Four recently identified biomarkers — septin-5, septin-7, neurochondrin, and adaptor protein-3B2 — have been added to the panel, and all four have been shown to respond to immunotherapy.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
In this month's "Hot Topic," Elitza Theel, Ph.D., shares the recommended approach to serologic testing for assessment or infection with coccidioides.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Cori Berg, M.S.N., R.N., instructor in nursing for the Center for Individualized[...]
This page includes updates posted to the site during the month of January.